Last updated: March 12, 2024
Sponsor: Yonsei University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Coronary Artery Disease
Heart Disease
Chest Pain
Treatment
Genoss DES
Clinical Study ID
NCT05448625
9-2022-0014
Ages > 19 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Subject is ≥ 19 years
- Subject has signed informed consent for data release
Exclusion
Exclusion Criteria:
- Subject did not sign informed consent for data release
- Known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any otheranticoagulation / antiplatelet therapy required for PCI, cobalt chromium, Sirolimus orcontrast media
- Pregnancy
- Subject with life expectancy less than 12 months
- Subject with cardiogenic shock
Study Design
Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Genoss DES
Phase:
Study Start date:
May 26, 2022
Estimated Completion Date:
December 31, 2026
Study Description
Connect with a study center
Yongin Severance Hospital
Yongin, Gyeonggi-do 16995
Korea, Republic ofActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.